{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070416","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.711760+00:00","generated_at":"2026-05-21T15:35:46.745981+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives","bullets":["Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.","Net loss $10.9M ($3.16/share) vs $7.9M ($4.62/share) in Q1 2024; R&D expense $7.6M.","Completed workforce reduction on April 30, 2025; repaid $3.5M loan to Oxford Finance.","FDA granted Orphan Drug and Fast Track designations for amezalpat in HCC.","TPST-1495 granted Orphan Drug for FAP; FDA allowed Phase 2 trial to proceed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070416","json":"https://secwatch.observer/filing/0000950170-25-070416.json","markdown":"https://secwatch.observer/filing/0000950170-25-070416.md","text":"https://secwatch.observer/filing/0000950170-25-070416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/0000950170-25-070416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/tpst-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T15:35:46.745981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}